MoonLake Immunotherapeutics

Stock Chart, Company Information, and Scan Results

$19.26(as of May 29, 11:58 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

MoonLake Immunotherapeutics Company Information, Fundamentals, and Technical Indicators

Stock Price$19.26
Ticker SymbolMLTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees130
CountyUSA
Market Cap$1,355.3M
EBIDTA-264.5M
10-Day Moving Average17.78
P/E Ratio-5.18
20-Day Moving Average17.64
Forward P/E Ratio0.00
50-Day Moving Average17.51
Earnings per Share-3.88
200-Day Moving Average21.55
Profit Margin-Infinity%
RSI57.38
Shares Outstanding73.6M
ATR1.00
52-Week High62.75
Volume566,632
52-Week Low5.95
Most Recent Support Level17.94
Book Value254.0M
Most Recent Resistance Level18.75
P/B Ratio5.24
Upper Keltner19.90
P/S RatioInfinity
Lower Keltner15.39
Debt-to-Equity Ratio19.90
Next Earnings Date08/03/2026
Cash Surplus252.4M
Next Ex-Dividend DateUnknown

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics In Our Stock Scanner

As of May 29, 2026
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cup and HandleScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.